Institution
Children's Hospital Oakland Research Institute
About: Children's Hospital Oakland Research Institute is a based out in . It is known for research contribution in the topics: Population & Human leukocyte antigen. The organization has 1568 authors who have published 2480 publications receiving 203418 citations.
Topics: Population, Human leukocyte antigen, Haplotype, Gene, Cholesterol
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The results suggest a moderately increased risk of CLP among women who use corticosteroids during early pregnancy, and this study included data on deliveries from the National Birth Defects Prevention Study, which is a population-based case-control study.
229 citations
••
Washington University in St. Louis1, Cincinnati Children's Hospital Medical Center2, Pennsylvania State University3, Emory University4, Children's Hospital Oakland5, Harvard University6, Children's Hospital Oakland Research Institute7, University of California, San Francisco8, University of Pittsburgh9, University of Colorado Denver10, University of Arizona11, Allegheny General Hospital12, University of New Mexico13, Wake Forest University14, Children's Memorial Hospital15, Boston Children's Hospital16, University of Virginia17, San Francisco General Hospital18
TL;DR: Among young children with histories of recurrent severe LRTIs, the use of azithromycin early during an apparent RTI compared with placebo reduced the likelihood of severe L RTI, and the development of antibiotic-resistant pathogens with this strategy.
Abstract: Importance Many preschool children develop recurrent, severe episodes of lower respiratory tract illness (LRTI). Although viral infections are often present, bacteria may also contribute to illness pathogenesis. Strategies that effectively attenuate such episodes are needed. Objective To evaluate if early administration of azithromycin, started prior to the onset of severe LRTI symptoms, in preschool children with recurrent severe LRTIs can prevent the progression of these episodes. Design, Setting, and Participants A randomized, double-blind, placebo-controlled, parallel-group trial conducted across 9 academic US medical centers in the National Heart, Lung, and Blood Institute’s AsthmaNet network, with enrollment starting in April 2011 and follow-up complete by December 2014. Participants were 607 children aged 12 through 71 months with histories of recurrent, severe LRTIs and minimal day-to-day impairment. Intervention Participants were randomly assigned to receive azithromycin (12 mg/kg/d for 5 days; n = 307) or matching placebo (n = 300), started early during each predefined RTI (child’s signs or symptoms prior to development of LRTI), based on individualized action plans, over a 12- through 18-month period. Main Outcomes and Measures The primary outcome measure was the number of RTIs not progressing to a severe LRTI, measured at the level of the RTI, that would in clinical practice trigger the prescription of oral corticosteroids. Presence of azithromycin-resistant organisms in oropharyngeal samples, along with adverse events, were among the secondary outcome measures. Results A total of 937 treated RTIs (azithromycin group, 473; placebo group, 464) were experienced by 443 children (azithromycin group, 223; placebo group, 220), including 92 severe LRTIs (azithromycin group, 35; placebo group, 57). Azithromycin significantly reduced the risk of progressing to severe LRTI relative to placebo (hazard ratio, 0.64 [95% CI, 0.41-0.98], P = .04; absolute risk for first RTI: 0.05 for azithromycin, 0.08 for placebo; risk difference, 0.03 [95% CI, 0.00-0.06]). Induction of azithromycin-resistant organisms and adverse events were infrequently observed. Conclusions and Relevance Among young children with histories of recurrent severe LRTIs, the use of azithromycin early during an apparent RTI compared with placebo reduced the likelihood of severe LRTI. More information is needed on the development of antibiotic-resistant pathogens with this strategy. Trial Registration clinicaltrials.gov Identifier:NCT01272635
229 citations
••
Geneva College1, Imperial College London2, University of Gothenburg3, Sahlgrenska University Hospital4, University of Milan5, National Institutes of Health6, University of Western Ontario7, Emory University8, Children's Hospital Oakland Research Institute9, Leipzig University10, University of Toronto11, University of Graz12, Heidelberg University13, University of Copenhagen14, Copenhagen University Hospital15, University of the Witwatersrand16, University of Düsseldorf17, University of São Paulo18, Hartford Hospital19, Hacettepe University20, State University of New York System21, Columbia University22
TL;DR: Long-term statin treatment is remarkably safe with a low risk of clinically relevant adverse effects as defined above, and the established cardiovascular benefits of statin therapy far outweigh the risk of adverse effects.
Abstract: Aims
To objectively appraise evidence for possible adverse effects of long-term statin therapy on glucose homeostasis, cognitive, renal and hepatic function, and risk for haemorrhagic stroke or cataract.
228 citations
••
Harvard University1, Massachusetts Institute of Technology2, Kaiser Permanente3, University of California, Berkeley4, Erasmus University Rotterdam5, Children's Hospital Oakland Research Institute6, University of California, San Francisco7, University of Chicago8, Karolinska Institutet9, University of Tasmania10, University of Cambridge11, Yale University12, Science Applications International Corporation13, Utrecht University14
TL;DR: The major histocompatibility complex (MHC) region is a critical region for MS susceptibility that harbors multiple risk alleles, and this study dissects the independent effects in the MHC.
Abstract: The major histocompatibility complex (MHC) region is strongly associated with multiple sclerosis (MS) susceptibility. HLA-DRB1*15:01 has the strongest effect, and several other alleles have been reported at different levels of validation. Using SNP data from genome-wide studies, we imputed and tested classical alleles and amino acid polymorphisms in 8 classical human leukocyte antigen (HLA) genes in 5,091 cases and 9,595 controls. We identified 11 statistically independent effects overall: 6 HLA-DRB1 and one DPB1 alleles in class II, one HLA-A and two B alleles in class I, and one signal in a region spanning from MICB to LST1. This genomic segment does not contain any HLA class I or II genes and provides robust evidence for the involvement of a non-HLA risk allele within the MHC. Interestingly, this region contains the TNF gene, the cognate ligand of the well-validated TNFRSF1A MS susceptibility gene. The classical HLA effects can be explained to some extent by polymorphic amino acid positions in the peptide-binding grooves. This study dissects the independent effects in the MHC, a critical region for MS susceptibility that harbors multiple risk alleles.
227 citations
••
TL;DR: A first-generation human-chimpanzee comparative genome map is presented and candidate positions, including two clusters on human chromosome 21 that suggest large, nonrandom regions of difference between the two genomes are detected.
Abstract: The recently released human genome sequences provide us with reference data to conduct comparative genomic research on primates, which will be important to understand what genetic information makes us human. Here we present a first-generation human-chimpanzee comparative genome map and its initial analysis. The map was constructed through paired alignment of 77,461 chimpanzee bacterial artificial chromosome end sequences with publicly available human genome sequences. We detected candidate positions, including two clusters on human chromosome 21 that suggest large, nonrandom regions of difference between the two genomes.
226 citations
Authors
Showing all 1568 results
Name | H-index | Papers | Citations |
---|---|---|---|
Frank B. Hu | 250 | 1675 | 253464 |
Bruce M. Psaty | 181 | 1205 | 138244 |
Bruce N. Ames | 158 | 506 | 129010 |
Rino Rappuoli | 132 | 816 | 64660 |
Robert S. Schwartz | 130 | 923 | 62624 |
Carlos López-Otín | 126 | 494 | 83933 |
Ronald M. Krauss | 120 | 438 | 77969 |
Robert S. Stern | 120 | 761 | 62834 |
Joan S. Brugge | 115 | 286 | 47965 |
Ewan Birney | 114 | 308 | 125382 |
Keith M. Sullivan | 105 | 447 | 39067 |
Bo Lönnerdal | 99 | 674 | 36297 |
Dennis E. Discher | 98 | 372 | 60060 |
Richard Reinhardt | 94 | 370 | 58076 |
Henry A. Erlich | 93 | 354 | 40295 |